Condition (MeSH)
Osteonecrosis
ClinicalTrials.gov lists 334 trials for Osteonecrosis or a narrower condition beneath it. Zimmer Biomet has the most among industry and government lead sponsors, with 49.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase (log scale)
1 more section with rows
258 of the 334 trials are tagged with Osteonecrosis itself; the rest are tagged with a narrower condition beneath it.
When did Osteonecrosis trials start? (31)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
- Other (Unknown)
Top of scale: 25
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 10 |
| 2025 | 16 |
| 2024 | 10 |
| 2023 | 13 |
| 2022 | 14 |
| 2021 | 13 |
| 2020 | 9 |
| 2019 | 5 |
| 2018 | 10 |
| 2017 | 23 |
Showing 10 of 31 earlier years.
Forecast of the full-year count, planned starts included, not rows of this table: about 7 trials starting in 2026 and about 11 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 28 percent and ran about 20 percent low against the count later registered; forecasts made before the year began were off by about 39 percent and ran about 37 percent low against the count later registered. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored. The 2026 forecast is below the 10 already registered with a 2026 start date: at the cutoff, 6 trials were already registered to start in October to December, more than the method's monthly average allows for, and the method does not use those planned starts.
Prediction, not a registry value: median of 36 months from start to primary completion across 14 trials still running at the 2026-10-09 snapshot; registered median of 52 months across 202 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Osteonecrosis trials in? (9)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 12 |
| Phase 1/2 | 6 |
| Phase 2 | 15 |
| Phase 2/3 | 1 |
| Phase 3 | 11 |
| Phase 4 | 33 |
| Not applicable | 100 |
| Observational | 154 |
| Unknown | 2 |
How many Osteonecrosis trials are recruiting? (9)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 9 |
| Recruiting | 28 |
| Enrolling by invitation | 11 |
| Active, not recruiting | 46 |
| Completed | 130 |
Showing 5 of 9 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Osteonecrosis trials? (11)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Zimmer Biomet | 49 |
| DePuy International | 17 |
| Medacta International SA | 15 |
| MicroPort Orthopedics Inc. | 15 |
| DePuy Orthopaedics | 11 |
Showing 5 of 11 sponsors.
Which drugs are being tested for Osteonecrosis? (1)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| PROPOFOL | 2 |
Interventions as named in the registry (14)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| acid Zoledronic | 6 |
| total knee arthroplasty | 4 |
| Hyperbaric Oxygen | 3 |
| Alendronate 20 mg | 3 |
| Ropivacaine 2 % | 2 |
Showing 5 of 14 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Osteonecrosis trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Non-Operative | 74 | 1 |
| General | 48 | 2 |
| Osteoarthritis | 40 | 2 |
| General SAE | 38 | 1 |
| Muscular/Connective Tissue (generic musculoskeletal) | 23 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Osteonecrosis? (160)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Avascular Necrosis and Minimal Trauma Fractures in Telomere Biology Disorders. | Clinical genetics | 2026 | Yes |
| Deep learning-based quantification of osteonecrosis using magnetic resonance images in Gaucher disease. | Bone | 2024 | Yes |
| Association of haemolysis markers, blood viscosity and microcirculation function with organ damage in sickle cell disease in sub-Saharan Africa (the BIOCADRE study). | British journal of haematology | 2023 | Yes |
| Interventions for managing medication-related osteonecrosis of the jaw. | The Cochrane database of systematic reviews | 2022 | Yes |
| American Association of Oral and Maxillofacial Surgeons' Position Paper on Medication-Related Osteonecrosis of the Jaws-2022 Update. | Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons | 2022 | Yes |
Showing 5 of 160 publications.
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| Osteonecrosis | 399158 | Exact | Orphadata Science knowledge files, Product 1 |
| Osteonecrosis | 399158 | Exact | Orphanet Rare Disease Ontology (ORDO) |
Sub-conditions in MeSH (2)
MeSH descendants one level down with at least one trial, most trials first.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence.